StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Investment analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Saturday. The firm set a “sell” rating on the stock.

InspireMD Stock Performance

NSPR stock opened at $2.45 on Friday. The company has a fifty day moving average price of $2.48 and a 200-day moving average price of $2.52. The company has a market capitalization of $61.08 million, a P/E ratio of -3.23 and a beta of 0.96. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.85.

InspireMD (NYSE:NSPR) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.06). InspireMD had a negative return on equity of 55.12% and a negative net margin of 350.35%. The firm had revenue of $1.51 million for the quarter, compared to analyst estimates of $1.38 million. During the same quarter last year, the company earned ($0.53) earnings per share. As a group, sell-side analysts forecast that InspireMD will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. McKinley Carter Wealth Services Inc. bought a new stake in InspireMD in the fourth quarter worth about $28,000. Mesirow Financial Investment Management Inc. purchased a new position in InspireMD during the first quarter valued at approximately $71,000. Finally, Rosalind Advisors Inc. grew its stake in InspireMD by 266.4% during the second quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after acquiring an additional 1,827,579 shares in the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.